CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma

CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma

Abstract The alkylating agent, temozolomide (TMZ), is the most commonly used chemotherapeutic for the treatment of glioblastoma (GBM). The anti-glioma effect of TMZ involves a complex response that includes G2-M cell cycle arrest and cyclin-dependent kinase 1 (CDK1) activation. While CDK1 phosphoryl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: David J. Voce, Giovanna M. Bernal, Kirk E. Cahill, Longtao Wu, Nassir Mansour, Clayton D. Crawley, Paige-Ashley S. Campbell, Ainhoa Arina, Ralph R. Weichselbaum, Bakhtiar Yamini
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/a43b98628f924851b3c674791b7711df
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares